Published online 16 July 2009
Haematologica, Vol 94, Issue 10, 1466-1467 doi:10.3324/haematol.2009.010702
Copyright © 2009 by Ferrata Storti Foundation
Thomas Clozel1 ,
Aline Renneville2 ,
Marion Venot1 ,
Claude Gardin1 ,
Charikleia Kelaidi1 ,
Geneviève Leroux1 ,
Virginie Eclache1 ,
Claude Preudhomme2 ,
Pierre Fenaux1,3 ,
Lionel Adès1,3
In AML with inv(16)/t(16;16), few studies are available: Schnittger et al. reported 6 relapses of CBFβ-MYH11 AML with an interval between molecular and hematologic relapse ranging from 1–5 months,8 similar to what they observed in AML with PML-RAR and AML1-ETO. By contrast, Stentoft et al. reported, in 4 relapsing inv(16)/t(16;16) AML, an interval between molecular and hematologic relapse of approximately one year, with a slow molecular progression rate of about 1-log per 100 days.8 In our patients ns. 2, 3 and 4, the increase in fusion transcript levels had comparable kinetics, while in our patient n. 1, it was even slightly slower, with a molecular progression rate of about 1-log per 130 days. 
we thank the staff of the Department of Clinical Haematology, Hôpital Avicenne, Bobigny for the care of the patients in this study.
Haematologica, Vol 94, Issue 10, 1466-1467 doi:10.3324/haematol.2009.010702
Copyright © 2009 by Ferrata Storti Foundation
Acute Myeloid Leukemia |
Slow relapse in acute myeloid leukemia with inv(16) or t(16;16)
1 Department of Hematology, Hôpital Avicenne, Assistance Publique Hôpitaux de Paris (AP-HP)/Paris 13 University
2 Department of Hematology, Biology and Pathology Center, CHRU of Lille, Cancer Research Institute, JP Aubert Center, INSERM, U-837, Lille, and Cancéropôle Nord Ouest
3 Inserm unit U 848, Institut Gustave Roussy, Villejuif; France
Correspondence: Lionel Adès, MD, Department of Haematology, Hôpital Avicenne, Assistance Publique Hôpitaux de Paris (AP-HP)/Universitè, Paris 13, France. Phone: international +33.1.48957055. Fax: international +33.1.489507058 E-mail:lionel.ades{at}avc.aphp.fr
Acute myeloid leukemia (AML) with inv(16)(p13q22) or t(16;16)(p13;q22), resulting in CBFβ-MYH11 fusion transcript detectable by RT-PCR and RQ-PCR, is associated with an overall good prognosis, relapses however still occur in 30–35 % of patients, and with higher frequency in older patients.1,2 Molecular relapse generally precedes hematologic relapse in AML with balanced translocations such as t(15;17) or t(8;21), but generally by only a few weeks or a few months.3–9 Fewer data are available in AML with inv(16)/t(16;16). In 4 of the 5 relapses we observed in AML with inv(16)/t(16;16), the interval between molecular and hematologic relapse was prolonged.
Between 2005 and 2009, 9 AML patients with inv(16) or t(16;16), with a median age of 60 years (range, 21–75) who had reached CR using French co-operative AML trials (anthracycline–cytarabine induction chemotherapy followed by consolidation chemotherapy with high-dose cytarabine, or intermediate dose cytarabine in elderly patients) at our center were prospectively monitored for minimal residual disease (MRD) based on CBFβ-MYH11 fusion transcript levels in bone marrow samples.
RQ-PCR was performed on bone marrow cells according to the Europe Against Cancer (EAC) Program recommendations for CBFβ-MYH11 fusion transcripts (type A, D or E), using Taqman® technology, on an ABI PRISM 7000 (Applied Biosystems).10 Quantification of CBFb-MYH11 fusion transcripts was normalized to the housekeeping ABL gene. Results were expressed by the ratio CBFβ-MYH11 copy number/ABL copy number x 100 (%).10 Median follow-up after CR achievement was 18 months (range, 3–33) and median number of MRD analyses per patient was 6 (range 1–9). Molecular relapse was defined as a 10-fold or greater increase in CBFβ-MYH11 transcript level compared to the lowest level achieved.
Five of the 9 patients relapsed, after 11–23 months, in the bone marrow (no extramedullary relapse was seen). In one of them, the interval between molecular relapse and hematologic relapse was short (one month). The 4 other hematologic relapses occurred slowly, and were preceded in all cases by molecular relapse detected in bone marrow samples, by ten (patient n. 1), six (patient n. 2), seven (patient n. 3) and eight (patient n. 4) months, respectively. Baseline characteristics of those 4 patients are shown in Table 1. Patients ns. 2 and 3 had c-KIT mutation in exon 8 and c-KIT D816V mutation, respectively (versus none of the patients who did not relapse) and patient n. 3 had N-RAS mutation, while no patient had FLT3-ITD or FLT3-835/I836 mutation. All 4 patients had achieved at least a 3-log reduction of the fusion transcript level, after induction therapy in 3 of them, and after the first consolidation course in patient n. 1 (Figure 1). During the period of isolated molecular relapse, blood counts and marrow aspirates remained normal in patients ns. 3 and 4, while cytopenias reappeared in patient n. 1 and abnormal marrow eosinophils in patient n. 2. A second CR was achieved in the 4 patients with chemotherapy, combined to gemtuzumab in 3 cases. Three of them were subsequently allografted, and all 4 patients were alive 2–11 months after hematologic relapse. In acute promyelocytic leukemia (APL), the median interval between molecular and hematologic relapse was 3–4 months in published litterature3–5 while in AML with t(8;21) it was generally less than six months6–8 and at a median of three months in our experience.9
|
View this table: [in a new window] [Download PPT slide] |
Table 1. Main characteristics of the 4 relapsing patients analyzed.
|
 View larger version (12K): [in a new window] [Download PPT slide] |
Figure 1. Minimal residual disease (MRD) sequentially measured by RQ-PCR in bone marrow samples in the 4 relapsing patients. MRD was expressed in CBFB-MYH11 copies per /100 ABL gene copies. Dots on curves represent MRD examinations. Full arrows indicate molecular relapse and empty arrows indicate hematologic relapse. Follow-up is in months.
|
Thus, AML with inv(16)/t(16;16) AML may frequently relapse more slowly than other types of AML with balanced translocations. This interval between molecular and hematologic relapse may justify frequent MRD monitoring in those patients, and therapeutic intervention before overt relapse.
Acknowledgments
we thank the staff of the Department of Clinical Haematology, Hôpital Avicenne, Bobigny for the care of the patients in this study.
References
 TOP References |
|---|
- Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 23:5705–17.
- Delaunay J, Vey N, Leblanc T, Fenaux P, Rigal-Huguet F, Witz F, et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood 2003;102:462–9.
[Abstract/Free Full Text] - Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F, et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RAR
fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial. Blood 1998;92:784–9.[Abstract/Free Full Text] - Cassinat B, de Botton S, Kelaidi C, Ades L, Zassadowski F, Guillemot I, et al. When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group). Leuk Res 2009;33:1178–82.[CrossRef][Web of Science][Medline]
- Gallagher RE, Yeap BY, Bi W, Livak KJ, Beaubier N, Rao S, et al. Quantitative real-time RT-PCR analysis of PML-RAR mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 2003;101:2521–8.
[Abstract/Free Full Text] - Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 2003;102:2746–55.
[Abstract/Free Full Text] - Tobal K, Newton J, Macheta M, Chang J, Morgenstern G, Evans PA, et al. Molecular quantification of minimal residual disease in acute myeloid leukemia with t(8;21) can identifiy patients in durable remission and predict clinical relapse. Blood 2000;95:815–9.
[Abstract/Free Full Text] - Stentoft J, Hokland P, Ostergaard M, Hasle H, Nyvold CG. Minimal residual core binding factor AMLs by real time quantitative PCR initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse. Leuk Res 2006;30:389–95.[CrossRef][Web of Science][Medline]
- Leroy H, de Botton S, Grardel-Duflos N, Darre S, Leleu X, Roumier C, et al. Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). Leukemia 2005;19:367–72.[CrossRef][Web of Science][Medline]
- Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program. Leukemia 2003;17:2318–57.[CrossRef][Web of Science][Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||